Dark

FGEN
FibroGen, Inc
stock NASDAQ

At Close

May 19, 2025 3:59:30 PM EDT

0.3126USD+2.157%(+0.0066)396,768

0.00Bid 0.00Ask 0.0000Spread

Pre-market

May 19, 2025 8:20:30 AM EDT

0.3299USD+7.810%(+0.0239)100

After-hours

May 19, 2025 4:05:30 PM EDT

0.3193USD+2.143%(+0.0067)534

OverviewOptionsHistoricalExchangesShortsNews

Jan 4, 2022

07:00AM EST FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the session will be available on January 10 at 7:00am EST. GlobeNewswire Inc

Dec 20, 2021

08:08AM EST FibroGen Exercises Exclusive License Option For HiFiBiO's CCR8 Program Benzinga

08:00AM EST -- Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGens preclinical development pipeline -- HiFiBiO to receive $35 million option exercise payment, potential milestones and royalties GlobeNewswire Inc

Nov 9, 2021

04:34PM EST FibroGen Q3 EPS $0.54 Up From $0.35 YoY, Sales $156.00M Beat $143.46M Estimate Benzinga

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 2, 2021

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences: GlobeNewswire Inc

Oct 26, 2021

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. GlobeNewswire Inc

Oct 25, 2021

07:00AM EDT FibroGen Announces Analyses from Roxadustat Global Phase 3 Program GlobeNewswire Inc

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

12:35PM EDT What 4 Analyst Ratings Have To Say About FibroGen Benzinga

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 Benzinga

05:04AM EDT Goldman Sachs Downgrades FibroGen to Sell, Lowers Price Target to $11 Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 25, 2021

01:26PM EDT FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial Benzinga

07:44AM EDT FibroGen, Inc. (FGEN) on Wednesday announced positive topline results from the Phase 2 study of roxadustat, dubbed Whitney, in chemotherapy-induced anemia (CIA). RTTNews

07:13AM EDT FibroGen Reports Positive Results From Phase 2 Trial Of Roxadustat For Chemotherapy Induced Anemia RTTNews

07:01AM EDT FibroGen Primary Efficacy Endpoint In Phase 2 Clinical Trial Of Roxadustat Was Met Benzinga

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Companys Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA). GlobeNewswire Inc

Aug 20, 2021

10:38AM EDT UPDATE: Raymond James Upgrades FibroGen To Market Perform Following Thursday-Evening News Of The Approval Of Roxadustat In The EU Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021 Benzinga

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

06:04AM EDT A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings; Crude Oil Edges Lower Benzinga

06:03AM EDT Pre-market Movers: GOVX, PROG, SONN, MRIN, RTTNews

05:31AM EDT Raymond James Upgrades FibroGen to Market Perform Benzinga

Aug 19, 2021

07:35PM EDT Astellas Pharma Inc. (TSE: 4503, President and CEO:Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO:Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO(roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). GlobeNewswire Inc

07:30PM EDT (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease PR Newswire

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

03:16PM EDT EC Site Shows Approval Of Evrenzo Benzinga

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

07:14AM EDT 3 Beaten Down Stocks that Could be Ready to Bounce Benzinga

Aug 16, 2021

07:15AM EDT FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer Benzinga

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September 6, 2021, and will remain with FibroGen through March 31, 2022 serving as Executive Advisor to the CEO to ensure a smooth transition. GlobeNewswire Inc

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

07:27AM EDT FibroGen Gets Complete Response Letter From FDA For Roxadustat For Anemia Of Chronic Kidney Disease RTTNews

07:05AM EDT FibroGen Shares To Resume Trade At 7:30 a.m. EDT Benzinga

07:00AM EDT Fibrogen Reports Received Complete Response Letter From FDA For Roxadustat For Anemia Benzinga

07:00AM EDT FibroGen, Inc.(NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD). GlobeNewswire Inc

06:56AM EDT Fibrogen Halted; Pending News Benzinga

Aug 10, 2021

07:57AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:51AM EDT SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to $30 Benzinga

Aug 9, 2021

04:16PM EDT FibroGen Q2 EPS $(1.45) Down From $(0.95) YoY, Sales $4.36M Down From $42.89M YoY Benzinga

04:01PM EDT Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 29, 2021

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 19, 2021

08:29AM EDT FibroGen Out-Licenses Recombinant Human Collagen-Based Biosynthetic Cornea Benzinga

07:06AM EDT Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology And Recombinant Collagen III Platform; Co. To Pay FibroGen $8M Up Front And Up To $64M In Milestones As Well As $46M In Commercial Milestones Benzinga

07:00AM EDT -- Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea GlobeNewswire Inc

Jul 16, 2021

02:36PM EDT Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher Benzinga

12:38PM EDT Mid-Day Market Update: Crude Oil Down 1%; FibroGen Shares Plummet Benzinga

11:09AM EDT Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views Benzinga

10:55AM EDT UPDATE: SVB Leerlink On FibroGen Price Target Trim: Given Failures Of Clinical Development And Lack Of Disclosure With Analytical And Regulatory Operations, Firm Believes It Is 'Appropriate' To Maintain A Low Probability Of Success Benzinga

10:52AM EDT SVB Leerlink Maintains Outperform On FibroGen But Lowers Price Target From $56 To $35 Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views Benzinga

10:15AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021 Benzinga

09:49AM EDT GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies Benzinga

08:09AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:20AM EDT FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall? Benzinga

06:46AM EDT B of A Securities Downgrades FibroGen to Neutral, Announces $29 Price Target Benzinga

06:20AM EDT FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall? Benzinga

05:28AM EDT Stifel Downgrades FibroGen to Hold, Lowers Price Target to $29 Benzinga

Jul 15, 2021

06:27PM EDT FibroGen Announces Outcome of FDA Advisory Committee Review of GlobeNewswire Inc

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 13, 2021

01:03PM EDT Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions Benzinga

Jul 12, 2021

07:07AM EDT FibroGen Appoints John Hunter As Chief Scientific Officer RTTNews

07:01AM EDT FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGens research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience. GlobeNewswire Inc

Jun 25, 2021

09:16AM EDT Astellas Pharma And FibroGen announce Positive CHMP Opinion For EVRENZO Benzinga

09:15AM EDT Astellas Receives Positive CHMP Opinion for GlobeNewswire Inc

09:01AM EDT Astellas Pharma, FibroGen: CHMP Of EMA Adopted Positive Opinion Relating To Use Of Roxadustat RTTNews

08:57AM EDT Astellas Receives Positive CHMP Opinion for EVRENZO(tm) (roxadustat) for Adult PR Newswire

Jun 17, 2021

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

08:30AM EDT FibroGen In-Licenses Three HiFiBiO Programs For Cancer, Autoimmune Settings Benzinga

07:01AM EDT FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease Benzinga

07:00AM EDT -- FibroGen Exclusively Licenses HiFiBiOs Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs -- Transformative Transaction for FibroGens Early-stage Pipeline -- HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All Three Programs, Plus Royalties GlobeNewswire Inc

Jun 16, 2021

08:01AM EDT FibroGen Announces Pamrevlumab Included In Pancreatic Cancer Action Network's Adaptive Clinical Trial Platform Benzinga

08:00AM EDT Pamrevlumab Included in Pancreatic Cancer Action GlobeNewswire Inc

Jun 14, 2021

07:40PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 10, 2021

07:00PM EDT Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN PR Newswire

Jun 9, 2021

09:29PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 8, 2021

10:51PM EDT FIBROGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN Business Wire

10:38PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

06:10PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

01:14PM EDT Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & GlobeNewswire Inc

Jun 7, 2021

11:03PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:10AM EDT Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against FibroGen, Inc. PR Newswire

Jun 4, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

01:20PM EDT FGEN DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

Jun 3, 2021

10:14AM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 2, 2021

10:01PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 1, 2021

07:03PM EDT Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. PR Newswire

May 31, 2021

10:15PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

05:14PM EDT FGEN Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

May 27, 2021

10:00AM EDT Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: GlobeNewswire Inc

May 26, 2021

10:45PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

03:54PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

12:05PM EDT Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action PR Newswire

May 24, 2021

10:48PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 23, 2021

04:09PM EDT Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

10:48AM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 21, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

10:26AM EDT DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in PR Newswire

May 19, 2021

11:30PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

10:00PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

02:02PM EDT Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

May 18, 2021

10:53PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

11:49AM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 17, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 16, 2021

01:22PM EDT Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Expanded Class Period PR Newswire

May 15, 2021

03:18PM EDT Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & GlobeNewswire Inc

May 14, 2021

10:51PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 13, 2021

10:16AM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 12, 2021

09:46PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 11, 2021

10:31PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

06:51PM EDT FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

09:20AM EDT HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in PR Newswire

May 10, 2021

11:15PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:03PM EDT FibroGen Q1 EPS $(0.78) Beats $(0.87) Estimate, Sales $38.40M Miss $41.79M Estimate Benzinga

04:01PM EDT -- Roxadustat net product revenue in China of $15.4 million, on a US GAAP basisTotal roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca, compared to $29.2 million last quarter FDA to hold Advisory Committee Meeting on Roxadustat NDA - tentative date July 15, 2021 GlobeNewswire Inc

11:20AM EDT Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for FibroGen, PR Newswire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 8, 2021

01:15PM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 7, 2021

10:40PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

07:05PM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action GlobeNewswire Inc

May 5, 2021

01:41PM EDT FGEN Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for PR Newswire

May 3, 2021

11:03PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

02:00PM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

11:00AM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action GlobeNewswire Inc

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. GlobeNewswire Inc

May 1, 2021

03:36PM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against FibroGen, PR Newswire

Apr 30, 2021

04:50PM EDT FibroGen, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit PR Newswire

Apr 29, 2021

01:31PM EDT Kessler Topaz Meltzer & Check, LLP Announces Investor Securities GlobeNewswire Inc

Apr 28, 2021

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 5:00 PM Eastern Time. GlobeNewswire Inc

Apr 26, 2021

10:24PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

12:01PM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 25, 2021

04:11PM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action GlobeNewswire Inc

Apr 24, 2021

11:50AM EDT Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of PR Newswire

Apr 23, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Apr 21, 2021

03:47PM EDT Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

Apr 20, 2021

10:54PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

04:15PM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 19, 2021

11:03PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

01:25PM EDT Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, PR Newswire

10:05AM EDT with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established PR Newswire

Apr 17, 2021

03:49PM EDT FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces GlobeNewswire Inc

Apr 15, 2021

07:02AM EDT FibroGen Receives Rare Pediatric Disease Designation From The FDA For Pamrevlumab For Treatment Of Duchenne Muscular Dystrophy Benzinga

07:00AM EDT FibroGen Receives Rare Pediatric Disease Designation from the U.S. GlobeNewswire Inc

Apr 14, 2021

11:29PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

02:59PM EDT FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a PR Newswire

Apr 13, 2021

06:43PM EDT Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud GlobeNewswire Inc

05:48PM EDT Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

Apr 12, 2021

10:05AM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims. GlobeNewswire Inc

08:41AM EDT Biotech company FibroGen Inc. (FGEN) announced Monday that the U.S. Food and Drug Administration has granted Fast Track designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy or DMD. RTTNews

07:24AM EDT FibroGen Says FDA Granted Fast Track Designation For Anti-CTGF Antibody, Pamrevlumab RTTNews

07:03AM EDT FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy Benzinga

07:00AM EDT FibroGen Receives Fast Track Designation from the U.S. FDA for GlobeNewswire Inc

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Apr 8, 2021

09:36AM EDT with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug PR Newswire

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Apr 7, 2021

04:14PM EDT Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims. GlobeNewswire Inc

03:12PM EDT Mid-Afternoon Market Update: Dow Falls 25 Points; Homology Medicines Shares Slide Benzinga

12:54PM EDT Mid-Day Market Update: Crude Oil Down Over 1%; FibroGen Shares Plummet Benzinga

10:39AM EDT (FGEN) Alert: Did You Lose Money on Your FibroGen Investment? Contact Johnson PR Newswire

09:49AM EDT Mid-Morning Market Update: Markets Mostly Higher; RPM Earnings Beat Views Benzinga

08:18AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

07:50AM EDT Mizuho Downgrades FibroGen to Neutral, Announces $29 Price Target Benzinga

07:31AM EDT SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to $56 Benzinga

06:26AM EDT HC Wainwright & Co. Downgrades FibroGen to Neutral Benzinga

06:14AM EDT JP Morgan Upgrades FibroGen to Neutral Benzinga

05:54AM EDT FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat Benzinga

05:45AM EDT FibroGen Announced FDA Advisory Committee to Review Roxadustat NDA Tentatively Scheduled for July 15, 2021 Benzinga

Apr 6, 2021

07:50PM EDT FibroGen Announces FDA Advisory Committee to Review Roxadustat New GlobeNewswire Inc

04:03PM EDT FibroGen Says Became Aware That Primary Cardiovascular Safety Analyses Of Roxadustat Included Post-Hoc Changes To Stratification Factors; Says 'Continues to be Confident in the Benefit / Risk Profile of Roxadustat' Benzinga

04:01PM EDT Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat GlobeNewswire Inc

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:43AM EDT B of A Securities Upgrades FibroGen to Buy, Announces $47 Price Target Benzinga

Mar 16, 2021

07:06AM EDT FibroGen Initiates LELANTOS-2 Second Phase 3 Clinical Study Of Pamrevlumab For Treatment Of Duchenne Muscular Dystrophy Benzinga

07:00AM EDT FibroGen, Inc.(NASDAQ: FGEN) announced the initiation of LELANTOS-2, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab orplacebo in combination with systemic corticosteroids in patients with ambulatory Duchenne muscular dystrophy (DMD). GlobeNewswire Inc

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 3, 2021

08:58AM EST Mid-Afternoon Market Update: Crude Oil Down 1.5%; Communication Systems Shares Spike Higher Benzinga

08:58AM EST Mid-Day Market Update: Nasdaq Down 100 Points; NanoViricides Shares Spike Higher Benzinga

08:57AM EST Mid-Morning Market Update: Markets Mostly Lower; Target Profit Tops Views Benzinga

Mar 2, 2021

02:57PM EST Mid-Afternoon Market Update: Crude Oil Down 1.5%; Communication Systems Shares Spike Higher Benzinga

12:11PM EST Mid-Day Market Update: Nasdaq Down 100 Points; NanoViricides Shares Spike Higher Benzinga

10:15AM EST Mid-Morning Market Update: Markets Mostly Lower; Target Profit Tops Views Benzinga

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021 Benzinga

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

08:00AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:36AM EST SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to $64 Benzinga

06:24AM EST Jefferies Downgrades FibroGen to Hold, Lowers Price Target to $45 Benzinga

Mar 1, 2021

04:33PM EST FibroGen, AstraZeneca Report FDA's Cardiovascular, Renal Drugs Advisory Committee Will Hold AdCom Meeting To Review New Drug Application For Roxadustat; Companies Have Not Received Date Yet Benzinga

04:07PM EST FibroGen Q4 EPS $(0.64) Up From $(1.12) YoY, Sales $65.00M Up From $7.97M YoY Benzinga

04:01PM EST Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million GlobeNewswire Inc

04:01PM EST FibroGen Provides Regulatory Update on Roxadustat GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 28, 2021

11:38AM EST Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 18, 2021

07:00AM EST FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. GlobeNewswire Inc

Feb 12, 2021

07:00AM EST FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 1, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2021 Benzinga

06:23AM EST HC Wainwright & Co. Initiates Coverage On FibroGen with Buy Rating, Announces Price Target of $58 Benzinga

Jan 27, 2021

06:07AM EST Fibrogen Said it Will Supply Roxadustat as Bulk Drug Product to Astellas for Commercial and Other Uses in Europe, Commonwealth of Independent States Benzinga

Dec 22, 2020

07:08AM EST FibroGen Doses First Patient In ZEPHYRUS-2 Phase 3 Trial Of Pamrevlumab In Patients With Idiopathic Pulmonary Fibrosis RTTNews

07:03AM EST FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 Benzinga

07:00AM EST FibroGen, Inc.(NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease. GlobeNewswire Inc

Dec 21, 2020

02:51PM EST Mid-Afternoon Market Update: Dow Turns Positive; uniQure Shares Slide Benzinga

12:13PM EST Mid-Day Market Update: Crude Oil Down 4%; 500.com Shares Spike Higher Benzinga

03:20AM EST The US Food and Drug Administration has extended the review period of FibroGen's (FGEN) the New Drug Application or NDA for Roxadustat by three months, with an updated action date set for March 20. RTTNews

Dec 18, 2020

05:01PM EST FibroGen Today Announced That The Fda Has Extended The Review Period Of The New Drug Application For Roxadustat For The Treatment Of Anemia Of Chronic Kidney Disease By Three Months Benzinga

04:59PM EST FibroGen, Inc.(Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) by three months. The updated Prescription Drug User Fee Act (PDUFA) action date is March 20, 2021. GlobeNewswire Inc

Dec 2, 2020

07:00AM EST New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndromes (MDS) regardless of ring sideroblast (RS) or baseline erythropoietinlevel GlobeNewswire Inc

Dec 1, 2020

08:00AM EST FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D., M.P.H. in that role. Dr. Yu will continue as Chief Medical Officer through December 20, 2020, the roxadustat PDUFA date, and will remain with FibroGen through March 15, 2021 serving as Executive Advisor to the CEO to support the transition. GlobeNewswire Inc

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 27, 2020

07:01AM EST FibroGen, Astellas Report Approval Of EVRENZO In Japan For Treatment Of Anemia Of Chronic Kidney Disease In Adult Patients Not In Dialysis Benzinga

07:00AM EST Astellas Receives Approval of EVRENZO (roxadustat) in GlobeNewswire Inc

02:31AM EST Astellas Pharma Inc. (ALPMY) and FibroGen, Inc. (FGEN) announced that Japan's Ministry of Health, Labour and Welfare approved EVRENZO (roxadustat) for the treatment of anemia of chronic kidney disease in adult patients not on dialysis. This approval triggers a milestone payment of $15 million by Astellas to FibroGen. RTTNews

02:08AM EST Astellas, FibroGen: Japan's MHLW Approved EVRENZO For Treatment Of Anemia Of CKD In Adult Patients Not On Dialysis RTTNews

02:02AM EST Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis PR Newswire

Nov 18, 2020

08:47AM EST FDA Letter Dated Nov. 13 Shows FDA Petitioned to Decline Approval Of FibroGen's Roxadustat Benzinga

Nov 12, 2020

04:52PM EST Fibro en Enters Into A Maser Service Agreement With Samsung Biologics Benzinga

Nov 6, 2020

10:33AM EST SVB Leerink Maintains Outperform on FibroGen, Raises Price Target to $92 Benzinga

07:00AM EST FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following healthcare conferences: GlobeNewswire Inc

Nov 5, 2020

04:42PM EST FibroGen Q3 EPS $0.35 Up From $(0.57) YoY, Sales $44.00M Up From $33.17M YoY Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 3, 2020

09:17AM EST Cramer Gives His Opinion On Jumia Technologies, Nio, More Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

07:00AM EDT FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. GlobeNewswire Inc

Oct 26, 2020

10:08AM EDT Benzinga's Top Upgrades, Downgrades For October 26, 2020 Benzinga

07:44AM EDT Raymond James Initiates Coverage On FibroGen with Underperform Rating Benzinga

Oct 22, 2020

10:18AM EDT FibroGen Highlights Presentation Of Late-Breaker Abstract Results On Associations Between Hemoglobin Levels, Cardiovascular Outcomes In Roxadustat-Treated Patients With Anemia Of Chronic Kidney Disease Benzinga

10:08AM EDT In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels 10 g/dL GlobeNewswire Inc

Oct 14, 2020

07:02AM EDT FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined Benzinga

07:00AM EDT Late-breaking abstracts explore cardiovascularoutcomes of patients with anemia in chronic kidney disease(CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse Cardiovascular Events (MACE) and MACE+ GlobeNewswire Inc

Oct 2, 2020

07:01AM EDT New Ventures Funds Rebrands as Scientia Ventures PR Newswire

.dark-mode .vbp2vX{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .vbp2vX{ color: #333333; background-color: white; border: 2px solid #333333; }FGENFibroGen, Incstock NASDAQ

FGEN
FibroGen, Inc
stock NASDAQ